Simon Dumesnil insider trades

Open-market stock purchases and sales by Simon Dumesnil, Director at Pasithea Therapeutics Corp, from SEC Form 4 filings since Aug 2, 2021.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -22%.

Recent trades

DateStockTradeValue
May 1, 2026KTTA Pasithea Therapeutics CorpBought (not open market)—
Nov 28, 2025KTTA Pasithea Therapeutics CorpBought$25K
Oct 24, 2025KTTA Pasithea Therapeutics CorpBought (not open market)—

Companies traded

  • KTTA Pasithea Therapeutics Corp: 1 buy, last May 1, 2026

Get free alerts when Simon Dumesnil files a new trade →